ELGAN Pharma

ELGAN Pharma is a clinical-stage neonatology-focused biotechnology company developing safe, tailored therapies to address medical problems and developmental difficulties common in babies born very early. The company has two leading clinical programs: ELGN-GI and ELGN-EYE. Both therapies address high unmet medical needs of preterm infants with no existing solutions to date. ELGN-GI promotes a faster maturation of an infant’s intestines, allowing them to rapidly reach full enteral feeding and become independent from parenteral nutrition while minimizing serious complications and reducing burden and costs to healthcare systems. The product has completed several clinical trials, including a successful phase 3, and is currently starting a second phase 2. ELGN-EYE is a local drug targeted at preventing vision impairment due to retinopathy of prematurity (ROP), a condition caused by the underdeveloped blood vessels in the eyes of premature babies at the time of birth. ROP is the leading cause of blindness in children worldwide. A phase 1 study of the product was successfully concluded and a phase 2 is currently launching.

ELGAN Pharma has raised $7.5M in total funding across 3 rounds. The company is currently at the A stage. Key investors include NGT HealthCare II, NGT3.

ELGAN Pharma was founded in 2018 by Miki Olshansky (Co-founder & CEO), Stav Zeldis (Co-founder & VP Regulatory Affairs).

ELGAN Pharma operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Materials & Substances, Nanomaterials. Target customers: Consumers, Demographics & Family, Babies, Healthcare & Life Sciences, Healthcare, Patients, Providers.

ELGAN Pharma is based in Wadi el-Haj Street 13, Nazareth, Israel, North District.